menu search

UTHR / United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2022 Results - Earnings Call Transcript

United Therapeutics Corporation (UTHR) CEO Martine Rothblatt on Q1 2022 Results - Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR ) Q1 2022 Results Conference Call May 4, 2022 9:00 AM ET Company Participants Dewey Steadman - Head, IR Martine Rothblatt - Chairperson, CEO Michael Benkowitz - President, COO Leigh Peterson - SVP, Product Development Patrick Poisson - EVP, Technical Operations Conference Call Participants Andreas Argyrides - Wedbush Securities Eun Yang – Jefferies Jessica Fye – JPMorgan Joseph Thome - Cowen & Company Operator Good morning, and welcome to the United Therapeutics Corporation First Quarter 2022 Earnings Webcast. My name is Abby, and I will be your conference operator today. Read More
Posted: May 4 2022, 12:06
Author Name: Seeking Alpha
Views: 110756

UTHR News  

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

United Therapeutics Corporation (UTHR) Q3 2023 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2023 Earnings Conference Call November 1, 2023 9:00 AM ET Company Participants Dewey Steadman – He more_horizontal

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings & Sales Beat Estimates

United Therapeutics (UTHR) third-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

By Zacks Investment Research
November 1, 2023

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.38 per share, beating the Zacks Consensus Estimate of $4.89 per share. This compares more_horizontal

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

By Seeking Alpha
October 22, 2023

United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision

United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a com more_horizontal

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

By Seeking Alpha
August 3, 2023

United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth More Than Justified

United Therapeutics Corporation (NASDAQ: UTHR) reported strong quarterly results, adding strength to its economic characteristics. The company's finan more_horizontal

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line. more_horizontal

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for United Therapeutics (UTHR) give a sense of how the business performed in the quarter ended June 2023, it co more_horizontal

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

By Zacks Investment Research
August 2, 2023

United Therapeutics (UTHR) Tops Q2 Earnings and Revenue Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $5.24 per share, beating the Zacks Consensus Estimate of $4.41 per share. This compares more_horizontal


Search within

Pages Search Results: